Open Nav

E-Scape Bio

  • Julie Anne Smith, E-Scape Bio Inc.

Company update

  • Date:Wednesday, October 17
  • Time:9:45 AM - 10:00 AM
  • Room:Elizabethan A
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:E-Scape Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. We are passionate about making a meaningful clinical impact for patients suffering from CNS diseases and believe in a genetically defined approach to achieving this goal.
  • Company
  • Company HQ City:South San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Julie Anne Smith
  • Year Founded:2015
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :ESB1609
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:ESB1609 S1P5 receptor agonist for neuronopathic lysosomal storage disorders.
  • Size of Last Investment Round:$63 Million
  • Total Amount Raised to Date, In All Rounds:$118 Million
Julie Anne Smith
E-Scape Bio Inc.